WO1995007354A1 - Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains - Google Patents
Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains Download PDFInfo
- Publication number
- WO1995007354A1 WO1995007354A1 PCT/EP1994/003039 EP9403039W WO9507354A1 WO 1995007354 A1 WO1995007354 A1 WO 1995007354A1 EP 9403039 W EP9403039 W EP 9403039W WO 9507354 A1 WO9507354 A1 WO 9507354A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- peptides
- virus
- amino acid
- nucleotide sequence
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 81
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 55
- 230000003472 neutralizing effect Effects 0.000 title claims abstract description 22
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 48
- 150000001413 amino acids Chemical class 0.000 claims abstract description 33
- 108010067390 Viral Proteins Proteins 0.000 claims abstract description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 18
- 230000004927 fusion Effects 0.000 claims abstract description 18
- 230000000890 antigenic effect Effects 0.000 claims abstract description 9
- 230000003248 secreting effect Effects 0.000 claims abstract description 7
- 230000007850 degeneration Effects 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 13
- 208000031886 HIV Infections Diseases 0.000 claims description 40
- 241000700605 Viruses Species 0.000 claims description 35
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 241000712461 unidentified influenza virus Species 0.000 claims description 24
- 239000000185 hemagglutinin Substances 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 101710154606 Hemagglutinin Proteins 0.000 claims description 13
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 13
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 13
- 101710176177 Protein A56 Proteins 0.000 claims description 13
- 241000701447 unidentified baculovirus Species 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 11
- 230000002906 microbiologic effect Effects 0.000 claims description 9
- 102000005348 Neuraminidase Human genes 0.000 claims description 8
- 108010006232 Neuraminidase Proteins 0.000 claims description 8
- 241000700618 Vaccinia virus Species 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 238000013048 microbiological method Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract description 7
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 230000003053 immunization Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 206010022000 influenza Diseases 0.000 description 9
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 8
- CNXOBMMOYZPPGS-NUTKFTJISA-N Lys-Trp-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O CNXOBMMOYZPPGS-NUTKFTJISA-N 0.000 description 8
- 108010092854 aspartyllysine Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 6
- ZXRQJQCXPSMNMR-XIRDDKMYSA-N Asp-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N ZXRQJQCXPSMNMR-XIRDDKMYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229940033332 HIV-1 vaccine Drugs 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- XFJKRRCWLTZIQA-XIRDDKMYSA-N Asn-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)N XFJKRRCWLTZIQA-XIRDDKMYSA-N 0.000 description 1
- IPPFAOCLQSGHJV-WFBYXXMGSA-N Asn-Trp-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(O)=O IPPFAOCLQSGHJV-WFBYXXMGSA-N 0.000 description 1
- ICTXFVKYAGQURS-UBHSHLNASA-N Asp-Asn-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O ICTXFVKYAGQURS-UBHSHLNASA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 101100394230 Caenorhabditis elegans ham-1 gene Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- VMKCPNBBPGGQBJ-GUBZILKMSA-N Glu-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N VMKCPNBBPGGQBJ-GUBZILKMSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100045395 Mus musculus Tap1 gene Proteins 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AVYVKJMBNLPWRX-WFBYXXMGSA-N Trp-Ala-Ser Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O)=CNC2=C1 AVYVKJMBNLPWRX-WFBYXXMGSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to peptides which elicit neutralizing antibodies against different strains and clinical isolates of HIV-1 , as well as to the antibodies elicited therewith, and also to the preparation of peptide- carrier combinations that efficiently present these peptides to the immune system. More particularly, this invention relates to the development of a vaccine against HIV-1.
- the acquired immunodeficiency syndrome is the late stage clinical manifestation of a long term persistent infec- tion with human immunodeficiency virus type 1 (HIV-1).
- Immune responses directed at the virus and at virus-infected cells during the persistent infection usually fail to mediate the resolution of the infection.
- Vaccines may elicit immune responses that can prevent the establishment of a persistent infection or even prevent the progression to AIDS.
- Most vaccine strategies against HIV-1 are directed at its surface glycoprotein gp160 which is made up of gp120 and gp41 and is responsible for binding the virus to the cellular receptor CD4 and for triggering subsequent fusion activity.
- the use of synthetic peptides as immunogens offers a number of advantages.
- the antibodies elicited by synthetic peptides have a predetermined specificity, and in the case of viruses, they can be selected to represent structures on the surface of virions.
- the synthetic polype tides are interesting also in that they can induce antibody responses not seen under normal conditions. For example, it is possible to induce neutralizing antibodies that have a broader reactivity than antibodies induced by whole proteins (Green et al., Cell (1982) 28:477).
- viruses such as vaccinia, polio or influenza can be used as vectors for immunogens.
- Rabbits inoculated with recombinant vaccinia virus containing sequences from hepatitis B surface antigen (HBsAg) , herpes simplex virus glycoprotein D, and influenza virus hemagglutinin produced antibodies to all three foreign antigens (Perkus et al., Science (1985) 229:981).
- a chimeric polio virus that expressed an epitope from gp41 of HIV-1 successfully induced neutralizing antibodies against HIV-1 in rabbits (Evans et al., Nature (1989) 339:385).
- influenza virus Since recently, it is also possible to change the genome of influenza virus by in vitro mutagenesis (Enami et al., Proc. Natl. Acad. Sci. USA (1990) 87:3802). By means of this tech ⁇ nique it was possible to engineer a stable attenuated in ⁇ fluenza A virus (Muster et al.,Pr ⁇ c. Natl Acad. Sci. USA (1991) 88:5177).
- An advantage of influenza virus in this context is the availability of many variants so that repeated vaccination may be possible. Furthermore, influenza virus induces strong secretory and cellular immune responses, which may be advantageous for an anti-HIV-1 vaccine approach.
- At least one, preferably all, of the above six amino acid sequences may then efficiently be presented to the immune system in order to induce formation and release of antibodies that show neutralizing activity against HIV-1 strains and/or which can inhibit cell fusion caused by these viruses.
- the amino acid sequence Glu Leu Asp Lys Trp Ala (ELDKWA) defining the epitope sequence of the human monoclonal antibody 2F5 (obtained from hybridoma cell line 2F5, PHLS deposit Nr.90091704; deposited 09/17/90) is connected with a Ser or both a Leu and Ser - which are located adjacent to the
- ELDKWA Sequence on gp41 defining the 2F5-epitope - thereby establishing the peptide sequences Glu Leu Asp Lys Trp Ala Ser (ELDKWAS) and Leu Glu Leu Asp Lys Trp Ala Ser (LELDKWAS) respectively, and inserted into a carrier molecule, namely the antigenic site B of the HA of influenza virus.
- the modified "chimeric" HA fusion protein carrying the foreign amino acid sequence ELDKWAS or LELDKWAS, very efficiently elicits antibodies directed at the presented ELDKWAS or LELDKWAS sequence upon application, preferably in the form of an injection, to the immune system of mammals, and humans in particular.
- the antibodies obtained by this method show neutralizing activity against different strains and/or clinical isolates of HIV-1.
- the mutations particularly affected the Asp (D) and/or Lys (K) amino acids in the centre of said sequence, thereby reducing the virus 1 susceptibility to getting neutralized by antibodies carrying the 2F5 epitope.
- This undesired kind of viral escape mechanism could, however, successfully be overcome by using those peptides according to the instant invention, wherein either Asp (D) or adjacent Lys (K) is replaced with Asparagine (N) .
- At least one, preferably a mixture of all six, of said six peptides may be used for the manufacture of a pharmaceutical to elicit antibodies that show neutralizing activity against different strains and/or clinical isolates of HIV-1 and/or that inhibit the fusion of cells caused by HIV-1.
- the same peptides may be used either each peptide alone or in a mixture with at least one other of said peptides, to manufacture a pharmaceutical to induce anti-HIV-1 IgA antibodies secreted from mucosal surfaces upon, preferably intranasal, application to mammals.
- At least one of said six peptides is linked to a carrier.
- a carrier can, for instance, be a virus, preferably in its attenuated and/or recombinant form.
- influenza virus, baculovirus or vaccinia virus may be used.
- Linking the small peptides to a carrier such as, for instance, a viral protein or a complete virus enhances the efficacy of antibody induction upon presentation of such chimeric peptide-carrier combinations or chimeric fusion proteins to the immune system.
- each of the above peptides as a fusion protein with a viral protein as the carrier, wherein at least one of the amino acid sequences according to the invention substitutes at least one part of the viral carrier protein or is inserted into at least one of the antigenic sites of the viral protein.
- said viral protein is the hemagglutinin (HA) of influenza virus, the neuraminidase (NA) of influenza virus or the surface antigen of hepatitis B virus.
- HA hemagglutinin
- NA neuraminidase
- it may be derived from a - preferably recombinant - baculovirus or vaccinia virus.
- the instant invention also relates to the use of any of the above identified peptides consisting of seven or eight amino acids and/or peptide-carrier combinations or fusion proteins for the manufacture of a pharmaceutical to elicit or induce antibodies that show neutralizing activity against different strains and/or clinical isolates of HIV-1 and/or that inhibit the fusion of cells caused by HIV-1. More particularly, it is intended to provide an effective vaccine based on at least one, preferably a mixture of all six, of said peptides and/or said six peptides linked to a carrier, for the prophylactic treatment of HIV-1 endangered individuals and/or the therapeutic treatment of HIV-1 infected patients, especially to prevent the progression of the infection to AIDS.
- said six peptides and/or said six peptides linked to a carrier are used to prepare and manufacture pharmaceutical formulations that - upon application to the mammalian immune system - lead to the induction of anti-HIV-1 IgA antibodies secreted from mucosal surfaces of the animal or human patients. Intranasal application is preferred in this case.
- said six peptides and/or peptide-carrier combinations of the instant invention may also be used for the manufacture of a pharmaceutical for the prophylaxis and prevention of endangered individuals from HIV-1 infection.
- the instant invention further relates to an antibody showing HIV-1 neutralizing activity and being capable of preventing fusion of cells caused by HIV-1, characterized in that it is elicited by one of the said six peptides.
- the said antibody is a secretory antibody, preferably an anti-HIV-1 IgA antibody, and advantageously being secreted by mucosal surfaces.
- the instant invention also refers to a process for the manufacture of anyone of said six peptides by either microbiological or chemical methods.
- said six peptides are chemically synthesized following standard biochemical procedures, preferably using an Applied Biosystems 431 Peptide Synthesizer.
- said amino acid sequences are obtained by a microbiological process comprising the steps of inserting a nucleotide sequence selected from the group consisting of
- Chimeric fusion proteins or peptide-carrier combinations may be manufactured according to an embodiment comprising linking an amino acid sequence selected from the group consisting of said six peptides, to a carrier, preferably a virus or viral protein, by chemical or microbiological methods.
- the process for the manufacture of the said six peptides linked to a carrier is microbiological and comprises the steps of linking a nucleotide sequence selected from the group consisting of
- nucleotide sequence corresponding to one of the amino acid sequences of the said six peptides; b) a nucleotide sequence hybridizing to one of the nucleotide sequences under a) ; c) a nucleotide sequence deduced from one of the nucleotide sequences under a) by degeneration;
- nucleotide sequence corresponding to an amino acid sequence of the carrier transferring the linked nucleotide sequences to a host organism, carrying out expression of the linked sequence using standard microbiological techniques, and isolating at least one, preferably a multitude, of said peptides linked to a carrier.
- the process for the manufacture of said six peptides linked to a carrier is characterized in that at least one of the nucleotide sequences selected from the group consisting of a) a nucleotide sequence corresponding to one of the amino acid sequences of said six peptides; b) a nucleotide sequence hybridizing to one of the nucleotide sequences under a) ; c) a nucleotide sequence deduced from one of the nucleotide sequences under a) by degeneration;
- nucleotide sequence corresponding to an amino acid sequence of a viral protein is linked with a nucleotide sequence corresponding to an amino acid sequence of a viral protein as the carrier, thereby substituting at least part of the nucleotide sequence corresponding to the amino acid sequence of the viral protein or being inserted into at least one site of said sequence corresponding to an antigenic site of the viral protein.
- the applied viral protein is selected from the group consisting of the hemagglutinin of influenza virus, neuraminidase of influenza virus and the surface antigen of hepatitis B virus, and in another characteristic embodiment, an influenza virus, baculovirus or vaccinia virus - each of them preferably in a recombinant form - is used as the host organism.
- Insertion of the sequences of said six peptides into the antigenic site B of the HA of influenza strains other than WSN, which strain is mainly referred to in the following examples, will equally lead to fusion proteins and/or chimeric viruses that elicit neutralizing anti-HIV-1 anti ⁇ bodies and prevent HIV-1-driven cell fusion.
- NA neuraminidase
- Example 1 Epitope mapping
- the epitope of the monoclonal antibody 2F5 was identified by immunoblotting using a method described by Towbin et al., Proc. Natl. Acad. Sci. USA (1979)76:4350.
- Peptides of over ⁇ lapping fragments of gp41 of HIV-1 isolate BH10 were cloned as fusion peptides with glutathiontransferase.
- the different fusion peptides were obtained through hybridization of gp41 corresponding oligonucleotides which were cloned between the Bam HI and the Eco RI site of the plasmid pGEX-2T (Pharma ⁇ cia) .
- the recombinant plasmids were transformed into the E.
- IPTG isopropylthiogalactoside
- the data from the immunoblotting show that the epitope of human monoclonal antibody 2F5 comprises the amino acid sequence ELDKWA corresponding to amino acids 662-667 of gp160.
- Fig. 1 illustrates the specificity of human monoclonal anti ⁇ body 2F5 (see Example 1 ) .
- Fig. 2 illustrates the construction of chimeric hemagglu- tinins that carry the 2F5-epitope sequence (see Example 2)
- Fig. 3 illustrates ELISA titers of antisera of mice immunized with the chimeric influenza viruses (see Example 3)
- Fig. 4 illustrates ELISA titers of mice immunized with cells infected with the recombinant baculoviruses (see Example 5).
- Fig.1 shows immuno blots of fusion peptides with overlapping fragments of gp160 of HIV-1 (isolate BH10).
- constructs that comprise amino acids 597 to 677 (lane 2) , 634 to 677 (lane 3) and 648 to 677 (lane 4) which were reactive with the antibody 2F5 did not show a positive reaction.
- the peptide containing the aminoacid sequence GLU LEU ASP LYS TRP ALA (amino acids 662-667, lane 2) was highly reactive with the antibody 2F5 whereas for peptides containing the aminoacid sequence LEU ASP LYS TRP ALA SER (LDKWAS, amino acids 663-668, lane 3) or ASP LYS TRP ALA SER LEU (DKWASL, amino acids 664-669, lane 4) reactivity with the monoclonal antibody was reduced.
- a peptide containing aminoacid sequence LEU GLU LEU ASP LYS TRP (LELDKW, amino acids 661-666, lane 1) showed no significant reactivity.
- the epitope of the monoclonal antibody comprises the amino acid sequence GLU LEU ASP LYS TRP ALA (ELDKWA) that corresponds to amino acids 662- 667 on gp160 of the HIV-1 BH10 isolate.
- ELDKWA amino acid sequence GLU LEU ASP LYS TRP ALA
- the sequence of the WSN HA is provided by Hiti et al. (J.Virol.41 ,730-734,1982) and the sequence of gp160 by the Swissprot database entry ENV$HIV10.
- Transfection of RNA de- rived from this plasmid into MDBK cells and selection and preparation of chimeric viruses was done according to Enami et al. (Proc.Natl.Acad. Sci. 87,3802-3805,1990) with modi ⁇ fications described by Enami and Palese (J.Virol.65, 2711- 2713, 1991).
- Example 3 Immunization and antibody response of mice immunized with the chimeric influenza viruses
- OF-1 mice were immunized with the chimeric influenza-ELDKWAS virus Imice M1 , M2, M3, M41 or influenza-L ELDKWAS virus (mouse M5) .
- Mice were first immunized with 102 TCID50 intranasally (i.n.) followed by an i.n. booster immunization with 5x105 TCID50 after 6 weeks, an intraperitoneal (i.p.) immunization with 20 ⁇ g sucrose-purified live virus after 3 weeks and a final boost with 20 ⁇ g of SDS-denatured virus in incomplete Freunds adjuvant after 3 more weeks intervals.
- mice were under ether anesthesia.
- mice were bled 12 days after the final boost, antisera were inactivated 1h at 56°C and ELISA titers and neutralizing activity of antisera was determined.
- Fig.3A shows the binding of influenza-ELDKWAS antisera to a glutathion S-transferase (GST) fusion peptide containing the sequence ELDKWA on its C-terminus.
- GST glutathion S-transferase
- 96-well microtitre plates were coated with the GST-ELDKWA fusion peptide at 4 ⁇ g/ml (100 ⁇ l/well) in car ⁇ bonate buffer, pH 9,6 for 4h at room temperature. Plates were then washed with PBS/0.05% Tween. Antiserum diluted in PBS/ 1% BSA/0.05% Tween was added and incubated for 1h at RT.
- Fig 3B The same procedure as described in Fig.3A was fol ⁇ lowed except that for detection of antibodies a goat anti- mouse IgA antibody, conjugated with horse-radish peroxidase was used. The neutralizing activity of the antisera was determined by syncytia inhibition assays. The reciprocal serum dilutions that inhibit syncytia formation by 50% (EC50) are shown in Table 1. Antisera from mice M1 - M3 neutralized the entire test panel at various serum dilutions. Antisera M4 and M5 neutralized HIV-1 isolates MN and RF but not IIIB. The antisera induced by the WSN wild-type virus did not neutral- ize any of the HIV-1 isolates tested at the lowest serum dilution (1 :20) .
- the indicator cell line AA-2 which is described by Chaffee et al., J. Exp. Med (1988) 168:605, and as virus inoculum frozen stocks of HIV-1 strains MN, RF and IIB were used. All virus stocks were diluted to 101-9-102.5 TCID50 per ml. Mouse-antisera were diluted 2-fold in medium and distributed in 96-well microtiter plates (4 replicas of each dilution) . 50 ⁇ l of virus was added to 50 ⁇ l of diluted antisera and the virus/antibody mixture was preincubated for 2h at 4°C.
- AA-2cells For infection, 100 ⁇ l of AA-2cells (5x106 cells/ml) were added to each well; presence of syncytia was recorded after 5 days as an indication of HIV-1 infection.
- Estimation of 50% inhibiting dose (EC50) was done according to Reed and Muench as described in Am. J. Hyg. (1938) 27:493. The reciprocal serum dilutions that inhibit syncytia formation by 50% (EC50) are shown.
- Example 4 Expression of chimeric hemagglutinins carrying the extended 2F5-epitopes by recombinant baculoviruses
- the chimeric hemagglutinins containing the said six peptides were prepared as described in Example 1.
- the coding sequence of these chimeric hemagglutinins was flanked by restriction enzyme site BamHI and inserted into the BamHI site of plasmid (Bluebac III, Invitrogen, San Diego CA) .
- Transfection exper ⁇ iments in order to obtain recombinant baculoviruses that contain the chimeric hemagglutinins were done according to methods described by Groebe et al., Nucleic. Acids Res. (1990) 18:4033, and Feigner et al., Proc. Natl. Acad. Sci. USA (1987) 84:7413.
- the resulting recombinant chimeric baculoviruses can be used to elicit HIV-1 neutralizing antibodies.
- Example 5 Immunization and antibody response of mice im- munized with cells infected by the recombinant baculoviruses
- Sf9 cells that were used for immunizations were infected by recombinant baculoviruses at a multiplicity of infection (MOD of 1-5, and harvested 3 days post infection. The cells were washed twice with PBS and resuspended in sterile PBS at a concentration of 5x 106 cells/ml. These cells specifically reacted with monoclonal antibody 2F5 in Western blots, indi ⁇ cating that these cells contained the hemagglutinin carrying the ELDKWAS or LELDKWAS sequence. Balb/cA mice were immunized with four intraperitoneal injections of 1x106 infected Sf9 cells at 2 weeks intervals (Van Wyyke Coelingh et al.
- Fig.4 shows the binding of the recombinant baculovirus derived antisera to a synthetic peptide comprising the sequence Gly Gly Gly Glu Leu Asp Lys Trp Ala (GGGELDKWA) in an ELISA that was performed as described in Example 2.
- Immunizations carried out by application of at least one, preferably a mixture, of said six peptides resulted in significantly improved IgG ELDKWA-specific ELISA titers. Furthermore, in contrast to immunizations using the ELDKWA sequence, immunizations with the said six peptides resulted also in a significant IgA response. Surprisingly, this IgA immune response was also triggered at the mucosal level.
- Example 6 IgA antibodies in respiratory secretions of Balb/c mice immunized with influenza-ELDKWAS virus.
- mice were immunized with 10 2 PFU intranassally and boosted after 4 weeks with 10 5 PFU by the same route.
- the third immunization was given intranasally (IN) or intraperitoneally (IP) with 10 7 PFU after 4 more weeks.
- Nasal washings were collected and pooled 8 weeks after the third immunization and reactivity of these samples with the peptide ELDKWA was determined by ELISA.
- WT pool nasal washings of mice immunized with the wild-type (WT) influenze virus were pooled and analyzed.
- the same immunization scheme as for the IN group was used (rf. Fig.5) .
- the elicited antibodies have primarily been produced by the nasal mucosa and it can be recognized that the antibody titers are unusually high. It can further be seen in Fig.5 that intranasal application of the influenza-ELDKWAS-virus leads to a higher concentration of HIV-1 neutralizing antibodies than intraperitoneal application.
- Example 7 IgA antibodies in intestinal secretions of Balb/c mice immunized with influenza-ELDKWAS virus
- mice were immunized with 10 2 PFU intranasally and boosted after 4 weeks with 10 5 PFU by the same route.
- the third immunization was given intranasallay (rf. Fig. 6a) or intraperitoneally (Fig. 6b) with 10 7 PFU after 4 more weeks.
- Faecal pellets containing the antibodies released from the intestinal mucosa were collected and extracted 8 weeks after the third immunization, and reactivity of these samples with the peptide ELDKWAwas determined by ELISA.
- IN 0, IN R, IN B and IN S are samples from mice that received the third immunization intranasally, and the samples IP 0, IP R, IP RS and IP S were collected from mice that received the third immunization intranasally, and the samples IP 0, IP R, IP RS and IP S were collected from mice that received the third immunization intranasally, and the samples IP 0, IP R, IP RS and IP S were collected from mice that received the third immun
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT94927602T ATE199260T1 (en) | 1993-09-11 | 1994-09-12 | PEPTIDES THAT INDUCE NEUTRALIZING ANTIBODIES AGAINST GENETICALLY DIVERGENT HIV-1 STRAINS |
AU76965/94A AU682893B2 (en) | 1993-09-11 | 1994-09-12 | Peptides that elicit neutralizing antibodies against genetically divergent HIV-1 strains |
UA96030897A UA43350C2 (en) | 1993-09-11 | 1994-09-12 | Peptide induced production antibodies having neutralizing activity concerning hiv-1 strains and/or isolates, and/or inhibite due to vil-1 injured cell fusion, farmaceutical agent for antibody formation, method for antibody obtaining, iga, antibody demonstrating counteractive activity neutralizing hiv-1 and/or inhibits due to vil-1 injured cell fusion |
EP94927602A EP0725825B1 (en) | 1993-09-11 | 1994-09-12 | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
CA002171544A CA2171544C (en) | 1993-09-11 | 1994-09-12 | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
JP7508473A JPH09502348A (en) | 1993-09-11 | 1994-09-12 | Peptides for inducing neutralizing antibodies against genetically branched HIV-1 strains |
HU9600587A HU219507B (en) | 1993-09-11 | 1994-09-12 | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
BR9407531A BR9407531A (en) | 1993-09-11 | 1994-09-12 | Peptides that cause the formation of neutralizing antibodies against genetically divergent strains of HIV-1 |
DE69426725T DE69426725T2 (en) | 1993-09-11 | 1994-09-12 | PEPTIDES INDUCING NEUTRALIZING ANTIBODIES AGAINST GENETICALLY DIVERGING HIV-1 STRAINS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93114631.0 | 1993-09-11 | ||
EP93114631 | 1993-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995007354A1 true WO1995007354A1 (en) | 1995-03-16 |
Family
ID=8213253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/003039 WO1995007354A1 (en) | 1993-09-11 | 1994-09-12 | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0725825B1 (en) |
JP (1) | JPH09502348A (en) |
CN (1) | CN1135237A (en) |
AT (1) | ATE199260T1 (en) |
AU (1) | AU682893B2 (en) |
BR (1) | BR9407531A (en) |
CA (1) | CA2171544C (en) |
CZ (1) | CZ287808B6 (en) |
DE (1) | DE69426725T2 (en) |
ES (1) | ES2156902T3 (en) |
HU (1) | HU219507B (en) |
PT (1) | PT725825E (en) |
RU (1) | RU2181379C2 (en) |
UA (1) | UA43350C2 (en) |
WO (1) | WO1995007354A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033219A1 (en) * | 1995-04-19 | 1996-10-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Monoclonal antibodies against hiv-1 and vaccines made thereof |
WO2000061618A1 (en) * | 1999-04-13 | 2000-10-19 | University Of Toronto | Fab-EPITOPE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING MONOCLONAL ANTIBODY 2F5 |
US6319890B1 (en) | 1996-12-30 | 2001-11-20 | Manfred P. Dierich | Inhibition of binding of complement Factor H |
WO2002032452A1 (en) * | 2000-08-18 | 2002-04-25 | Tsinghua University | Composition for aids and method producing it |
FR2851165A1 (en) * | 2003-02-19 | 2004-08-20 | Aventis Pasteur | Using helix C of gp41, containing several mutations of amino acids to alanine, as antigen for generating neutralizing antibodies for treatment or prevention of human immune deficiency virus infection |
US8956627B2 (en) | 2007-04-13 | 2015-02-17 | Duke University | Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates |
US9402893B2 (en) | 2005-04-12 | 2016-08-02 | Duke University | Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4602547B2 (en) * | 1998-03-23 | 2010-12-22 | トリメリス,インコーポレーテッド | Methods and compositions for peptide synthesis |
EP1754715A1 (en) | 2005-08-19 | 2007-02-21 | Bundesrepublik Deutschland vertreten durch das Bundesminsterium für Gesundheit, dieses vertr. durch das Robert-Koch-Institut | Vaccine on the basis of virus-neutralising antibodies |
AP3402A (en) * | 2009-02-06 | 2015-08-31 | Mymetics Corp | Splitting GP41 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0570357A2 (en) * | 1992-05-14 | 1993-11-18 | Polymun Scientific Immunbiologische Forschung GmbH | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5817767A (en) * | 1993-02-24 | 1998-10-06 | Progenics Pharmaceuticals, Inc. | Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same |
-
1994
- 1994-09-12 ES ES94927602T patent/ES2156902T3/en not_active Expired - Lifetime
- 1994-09-12 HU HU9600587A patent/HU219507B/en not_active IP Right Cessation
- 1994-09-12 UA UA96030897A patent/UA43350C2/en unknown
- 1994-09-12 CZ CZ1996741A patent/CZ287808B6/en not_active IP Right Cessation
- 1994-09-12 AU AU76965/94A patent/AU682893B2/en not_active Ceased
- 1994-09-12 JP JP7508473A patent/JPH09502348A/en not_active Ceased
- 1994-09-12 DE DE69426725T patent/DE69426725T2/en not_active Expired - Fee Related
- 1994-09-12 RU RU96108781/13A patent/RU2181379C2/en not_active IP Right Cessation
- 1994-09-12 CN CN94194035A patent/CN1135237A/en active Pending
- 1994-09-12 PT PT94927602T patent/PT725825E/en unknown
- 1994-09-12 AT AT94927602T patent/ATE199260T1/en not_active IP Right Cessation
- 1994-09-12 EP EP94927602A patent/EP0725825B1/en not_active Expired - Lifetime
- 1994-09-12 CA CA002171544A patent/CA2171544C/en not_active Expired - Fee Related
- 1994-09-12 WO PCT/EP1994/003039 patent/WO1995007354A1/en active IP Right Grant
- 1994-09-12 BR BR9407531A patent/BR9407531A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0570357A2 (en) * | 1992-05-14 | 1993-11-18 | Polymun Scientific Immunbiologische Forschung GmbH | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates |
Non-Patent Citations (6)
Title |
---|
ALLAWAY ET AL.: "Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. 7, July 1993 (1993-07-01), pages 581 - 587 * |
BROLIDEN ET AL.: "Identification of human neutralizing-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 89, January 1992 (1992-01-01), WASHINGTON US, pages 461 - 465 * |
EVANS ET AL.: "An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies", NATURE., vol. 339, no. 6223, 1 June 1989 (1989-06-01), LONDON GB, pages 385 - 388 * |
JAVAHERIAN ET AL.: "Broadly neutralising antibodies elicited by the hypervariable neutralizing domain of HIV-1", SCIENCE., vol. 250, no. 4987, 14 December 1990 (1990-12-14), LANCASTER, PA US, pages 1590 - 1593 * |
MUSTER ET AL.: "A conserved neutralizing epitope on gp41 of human immunideficiency virus type 1", JOURNAL OF VIROLOGY, vol. 67, no. 11, November 1993 (1993-11-01), pages 6642 - 6647 * |
VANINI ET AL.: "Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies", AIDS, vol. 7, no. 2, February 1993 (1993-02-01), LONDON, UK., pages 167 - 174 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996033219A1 (en) * | 1995-04-19 | 1996-10-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Monoclonal antibodies against hiv-1 and vaccines made thereof |
US6319890B1 (en) | 1996-12-30 | 2001-11-20 | Manfred P. Dierich | Inhibition of binding of complement Factor H |
WO2000061618A1 (en) * | 1999-04-13 | 2000-10-19 | University Of Toronto | Fab-EPITOPE COMPLEX FROM THE HIV-1 CROSS-NEUTRALIZING MONOCLONAL ANTIBODY 2F5 |
US6482928B1 (en) | 1999-04-13 | 2002-11-19 | Aventis Pasteur Limited And University Of Toronto | Fab′-epitope complex from HIV-1 cross-neutralizing monoclonal antibody 2F5 |
US7342090B1 (en) | 1999-04-13 | 2008-03-11 | University Of Toronto | Fab-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5 |
WO2002032452A1 (en) * | 2000-08-18 | 2002-04-25 | Tsinghua University | Composition for aids and method producing it |
FR2851165A1 (en) * | 2003-02-19 | 2004-08-20 | Aventis Pasteur | Using helix C of gp41, containing several mutations of amino acids to alanine, as antigen for generating neutralizing antibodies for treatment or prevention of human immune deficiency virus infection |
US9402893B2 (en) | 2005-04-12 | 2016-08-02 | Duke University | Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies |
US9717789B2 (en) | 2005-04-12 | 2017-08-01 | Duke University | Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies |
US10588960B2 (en) | 2005-04-12 | 2020-03-17 | Duke University | Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies |
US8956627B2 (en) | 2007-04-13 | 2015-02-17 | Duke University | Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1135237A (en) | 1996-11-06 |
DE69426725T2 (en) | 2001-09-06 |
AU682893B2 (en) | 1997-10-23 |
HU219507B (en) | 2001-04-28 |
JPH09502348A (en) | 1997-03-11 |
ES2156902T3 (en) | 2001-08-01 |
CA2171544A1 (en) | 1995-03-16 |
ATE199260T1 (en) | 2001-03-15 |
HUT76102A (en) | 1997-06-30 |
UA43350C2 (en) | 2001-12-17 |
HU9600587D0 (en) | 1996-05-28 |
RU2181379C2 (en) | 2002-04-20 |
CZ74196A3 (en) | 1996-07-17 |
EP0725825B1 (en) | 2001-02-21 |
CA2171544C (en) | 2003-06-24 |
CZ287808B6 (en) | 2001-02-14 |
AU7696594A (en) | 1995-03-27 |
PT725825E (en) | 2001-08-30 |
DE69426725D1 (en) | 2001-03-29 |
BR9407531A (en) | 1997-08-26 |
EP0725825A1 (en) | 1996-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0570357B1 (en) | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates | |
McLain et al. | Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus | |
US5591823A (en) | Expression of specific immunogens using viral antigens | |
HU et al. | Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160 | |
JP2006020635A (en) | Antigenically-marked non-infectious retrovirus-like particle | |
JPH08505769A (en) | Methods for obtaining the natural domains of viral membrane proteins, especially their use as vaccines against HIV | |
EP0725825B1 (en) | Peptides that elicit neutralizing antibodies against genetically divergent hiv-1 strains | |
JP2009005706A (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
HUT67011A (en) | Derivatives opf gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant | |
EP1466924B9 (en) | Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV | |
US7056519B2 (en) | Methods for inducing HIV-neutralizing antibodies | |
CA2500401A1 (en) | Antigenic peptides | |
Kalyan et al. | Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1 | |
US5691170A (en) | Generation of hybrid genes and proteins by virus-mediated recombination | |
Weijer et al. | Induction of feline leukaemia virus-neutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene | |
WO2006029338A2 (en) | Modified hiv-1 envelope proteins | |
Steimer et al. | HIV-1 neutralization directed to epitopes other than linear V3 determinants | |
JP4317912B2 (en) | AIDS vaccine | |
Corvaisier et al. | Cross-reactive and group-specific immune responses to a neutralizing epitope of the human respiratory syncytial virus fusion protein | |
WO1995007099A1 (en) | Vaccine and process for producing the same | |
WO1994016084A1 (en) | Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94194035.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV1996-741 Country of ref document: CZ Ref document number: 2171544 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1996 612959 Country of ref document: US Date of ref document: 19960513 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-741 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1994927602 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994927602 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1996-741 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994927602 Country of ref document: EP |